Amicus Therapeutics Inc

NASDAQ:FOLD   2:23:30 PM EDT
23.24
+0.61 (+2.70%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)6.02B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$69.41 Million
Adjusted EPS-$0.23
See more estimates
10-Day MA$22.60
50-Day MA$18.52
200-Day MA$14.04
See more pivots

AMICUS THERAPEUTICS INC Stock, NASDAQ:FOLD

1 CEDAR BROOK DRIVE, CRANBURY, NJ 08512
United States of America
Phone: (609) 662-2000
Number of Employees: 508

Description

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease. It is conducting a Phase 1/2 clinical study of ATB200-02 to investigate pompe treatment paradigm in pompe patients. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.